Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nu-Med Plus, Inc. (NUMD)
USD0.02
+0.00 (+0.00%)
US OTC Healthcare Medical - Devices
Address
455 East 500 South 84111
Salt Lake City, UT, US
Salt Lake City, UT, US
CEO
William R. Colvin
Website
nu-medplus.com
IPO
2014-09-25
CIK 1543637 ISIN US67021R1041
Description
Nu-Med Plus, Inc. is a global medical technology firm dedicated to the innovation, refinement, and commercialization of various medical instruments. The company's offerings include a diverse array of nitric oxide delivery systems, such as specialized units for hospital environments, clinical applications, and research settings, alongside a mobile, rechargeable device designed for portable nitric oxide gas administration. Serving a broad spectrum of healthcare entities, its primary clients consist of hospitals, integrated health systems, and the wider medical professional community. Nu-Med Plus, Inc. was founded in 2011 and maintains its corporate headquarters in Salt Lake City, Utah.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.02
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13.0K
Beta
-2.39
Float Shares
45.92M
Free Float %
55.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -33.07% | -21.54% | -33.33% | -58.08% | -40.97% | -79.60% | -21.54% | -83.03% | -97.92% | -98.64% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.02
Quality scores
Altman Z-Score
-2,008.20
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%+12.5% Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%— Q1'26: +31.1% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-2.30× Q1'26: -2.33× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Wendy P. Smith | 25.99M | 32.80% | 25.99M | — | 25.99M | 10.00 | IN | United States | 2021-04-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-07 | Robins Jeffrey Lynn | Director | A-Award | A | Common Stock | 200,000 | 0.02 | 3.8K | 5,200,000 | — | ↗ |
| 2023-11-07 | HAYDE WILLIAM C | Director / Officer | A-Award | A | Common Stock | 1,000,000 | 0.02 | 19.0K | 1,000,000 | — | ↗ |
| 2022-09-12 | HAYDE WILLIAM C | Officer | — | D | Common Stock | 0 | 0.00 | — | 2,200,000 | — | ↗ |
| 2021-03-02 | Smith Wendy P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 500,000 | — | ↗ |
| 2016-08-05 | Morrison Craig | Director / Officer | J-Other | D | Common Stock | 2,000,000 | 0.00 | — | 2,000,000 | — | ↗ |
| 2015-08-01 | MERRELL KEITH L | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 4,181,250 | — | ↗ |
| 2015-04-23 | Earl Brett J. | Director / Officer | A-Award | A | Common Stock | 800,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2015-01-26 | Tait Thomas A | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2015-01-26 | Earl Brett J. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 200,000 | — | ↗ |
| 2015-01-26 | Christensen Mark Edward | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,010,000 | — | ↗ |
| 2013-09-02 | Tait Thomas A | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2013-02-10 | Robins Jeffrey Lynn | Director / Officer / 10% Owner | — | D | Common stock | 0 | 0.00 | — | 5,000,000 | — | ↗ |
| 2013-02-10 | Morrison Craig | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2013-02-10 | Moon William G | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
83.55M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2017 | Jeffrey L. Robins CEO | 42.6K | — | — | — | — | — | 42.6K | 0.00% | ↗ |
| 2 | 2017 | Keith L. Merrell CFO | — | — | 38.7K | — | — | — | 38.7K | 100.00% | ↗ |
| 3 | 2016 | Keith L. Merrell CFO | — | — | 78.9K | — | — | — | 78.9K | 100.00% | ↗ |
| 4 | 2016 | Jeffrey L. Robins CEO | 42.6K | — | — | — | — | — | 42.6K | 0.00% | ↗ |
| 5 | 2015 | Keith L. Merrell CFO | — | — | 135.0K | — | — | — | 135.0K | 100.00% | ↗ |
| 6 | 2015 | Jeffrey L. Robins CEO | 42.6K | — | — | — | — | — | 42.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2018-03-23 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Craig W. Morrison | Chair of the Medical Advisory Committee | — | — |
| Keith L. Merrell | Chief Financial Officer, Principal Accounting Officer, Treasurer, Secretary & Director | — | male |
| William Hayde | Executive Chairman | — | male |
| William R. Colvin | President, Chief Executive Officer & Director | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NUMD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
